Have a personal or library account? Click to login
Treatment of Secondary Chorea: A Review of the Current Literature Cover

Treatment of Secondary Chorea: A Review of the Current Literature

Tremor and Other Hyperkinetic Movements
Volume 10 (2020): Issue 0
By: Erin Feinstein and  Ruth Walker  
Open Access
|Jul 2020

References

  1. 1Khouzam HR. Identification and management of tardive dyskinesia: A case series and literature review. Postgrad. Med. 2015; 127: 726–37. DOI: 10.1080/00325481.2015.1074031
    Back to article
  2. 2Hermann A, Walker, RH. Diagnosis and Treatment of Chorea Syndromes. Curr. Neurol. Neurosci. Rep. 2015; 15. DOI: 10.1007/s11910-014-0514-0
    Back to article
  3. 3Carroll E, Sanchez-ramos J. Hyperkinetic movement disorders associated with HIV and other viral infections. In: Handbook of clinical neurology. 2011; 100: 323–334 DOI: 10.1016/B978-0-444-52014-2.00025-2
    Back to article
  4. 4Walker K, Brink A, Lawrenson, J Mathiassen W, Wilmshurst, JM. Treatment of sydenham chorea with intravenous immunoglobulin. J. Child Neurol. 2012; 27: 147–55 DOI: 10.1177/0883073811414058
    Back to article
  5. 5Kirvan CA, Swedo SE, Heuser, JS, Cunningham MW. Mimicry and autoantibody-mediated neuronal cell signaling in Sydenham chorea. Nat. Med. 2003; 9: 914–920. DOI: 10.1038/nm892
    Back to article
  6. 6Doyle F, et al. Infusion of Sydenham’s chorea antibodies in striatum with up-regulated dopaminergic receptors: A pilot study to investigate the potential of SC antibodies to increase dopaminergic activity. Neurosci. Lett. 2012; 523: 186–189. DOI: 10.1016/j.neulet.2012.06.073
    Back to article
  7. 7Walker KG, Wilmshurst JM. An update on the treatment of Sydenham’s chorea: the evidence for established and evolving interventions. Ther. Adv. Neurol. Disord. 2010; 3: 301–9 DOI: 10.1177/1756285610382063
    Back to article
  8. 8Demiroren K, et al. Sydenham’s chorea: a clinical follow-up of 65 patients. J. Child Neurol. 2007; 22: 550–4 DOI: 10.1177/0883073807302614
    Back to article
  9. 9Peña J, Mora E, Cardozo J, Molina O, Montiel C. Comparison of the efficacy of carbamazepine, haloperidol and valproic acid in the treatment of children with Sydenham’s chorea: Clinical follow-up of 18 patients. Arq. Neuropsiquiatr. 2002; 60: 374–377. DOI: 10.1590/S0004-282X2002000300006
    Back to article
  10. 10Alvarez LA, Novak G. Valproic acid in the treatment of Sydenham chorea. Pediatr. Neurol. 1985; 1: 317–319 DOI: 10.1016/0887-8994(85)90037-2
    Back to article
  11. 11Garvey MA, Snider LA, Leitman SF, Werden R, Swedo SE. Treatment of Sydenham’s Chorea with Intravenous Immunoglobulin, Plasma Exchange, or Prednisone. J. Child Neurol. 2005; 20: 424–429. DOI: 10.1177/08830738050200050601
    Back to article
  12. 12Spagnoli C, Cantalupo G, Piccolo B, Cerasti D, Pisani F. Unusual trigeminal autonomic pain heralding hemichorea due to Zoster Sine herpete vasculopathy. Pediatr. Neurol. 2013; 49; 205–208. DOI: 10.1016/j.pediatrneurol.2013.04.003
    Back to article
  13. 13Pulickal AS, Ramachandran S, Rizek P, Narula P, Schubert R. Chorea and Developmental Regression Associated With Human Herpes Virus-6 Encephalitis. Pediatr. Neurol. 2013; 48; 249–251. DOI: 10.1016/j.pediatrneurol.2012.11.010
    Back to article
  14. 14Zajkowska J, et al. Chorea and tick-borne encephalitis, Poland. Emerg. Infect. Dis. 2013; 19: 1544–5. DOI: 10.3201/eid1909.130804
    Back to article
  15. 15Prasuhn J, et al. Transient Generalized Chorea in Influenza A Encephalopathy. Tremor Other Hyperkinet. Mov. (N. Y). 2018; 8: 591. DOI: 10.5334/tohm.422
    Back to article
  16. 16Cunha BA, Kang S, Chandrankunnel JG. West Nile Virus (WNV) infection presenting as acute chorea. Travel Med. Infect. Dis. 2012; 10: 52–53. DOI: 10.1016/j.tmaid.2011.10.002
    Back to article
  17. 17Chambers RHM, Gooden MA, Gilbert TDE, Jackson ST. Childhood chorea-encephalopathy associated with recent parvovirus B19 infection in two Jamaican children. Ann. Trop. Paediatr. 2010; 30: 339–344. DOI: 10.1179/146532810X12858955921438
    Back to article
  18. 18Ozer F, Tiras R, Ozben S, Erol C. Chorea as the presentating feature of neurosyphilis. Neurol. India. 2009; 57: 347. DOI: 10.4103/0028-3886.53277
    Back to article
  19. 19Pereira LS, Wu AP, Kandavel G, Memarzadeh F, McCulley TJ. Vitreitis and movement disorder associated with neurosyphilis and human immunodeficiency virus (HIV) infection: case report. Arq. Bras. Oftalmol. 2008; 71: 717–718. DOI: 10.1590/S0004-27492008000500020
    Back to article
  20. 20Jones AL, Bouchier, IAD. A Patient with Neurosyphilis Presenting as Chorea. Scott. Med. J. 1993; 38: 82–84. DOI: 10.1177/003693309303800309
    Back to article
  21. 21Trocello J-M, Blanchet A, Bourdain F, Meyohas M-C, Vidailhet, M. Resolution of choreic movements associated with HIV encephalitis with anti-retroviral therapy. Rev. Neurol. (Paris). 2006; 162: 89–91. DOI: 10.1016/S0035-3787(06)74986-4
    Back to article
  22. 22Sanchez-Ramos JR, Factor SA, Weiner WJ, Marquez J. Hemichorea-hemiballismus associated with acquired immune deficiency syndrome and cerebral toxoplasmosis. Mov. Disord. 1989; 4: 266–73. DOI: 10.1002/mds.870040308
    Back to article
  23. 23Piccolo I, et al. Chorea in patients with AIDS. Acta Neurol. Scand. 1999; 100: 332–6. DOI: 10.1111/j.1600-0404.1999.tb00406.x
    Back to article
  24. 24Maggi P, et al. Choreoathetosis in acquired immune deficiency syndrome patients with cerebral toxoplasmosis. Mov. Disord. 1996; 11: 434–436. DOI: 10.1002/mds.870110414
    Back to article
  25. 25Navia BA, et al. Cerebral toxoplasmosis complicating the acquired immune deficiency syndrome: clinical and neuropathological findings in 27 patients. Ann. Neurol. 1986; 19: 224–38. DOI: 10.1002/ana.410190303
    Back to article
  26. 26Estrada-Bellmann I, Camara-Lemarroy CR, Flores-Cantu H, Calderon-Hernandez HJ, Villareal-Velazquez HJ. Hemichorea in a patient with HIV-associated central nervous system histoplasmosis. Int. J. STD AIDS. 2014; 27: 75–7. DOI: 10.1177/0956462414564608
    Back to article
  27. 27Habal R, Sauter D, Olowe O, Daras M. Cocaine and chorea. Am. J. Emerg. Med. 1991; 9: 618–20. DOI: 10.1016/0735-6757(91)90125-4
    Back to article
  28. 28Narula N, Siddiqui F, Katyal N, Krishnan N, Chalhoub M. Cracking the Crack Dance: A Case Report on Cocaine-induced Choreoathetosis. Cureus. 2017; 9: e1981. DOI: 10.7759/cureus.1981
    Back to article
  29. 29Ford JB, Albertson TE, Owen KP, Sutter ME, McKinney WB. Acute, Sustained Chorea in Children After Supratherapeutic Dosing of Amphetamine-Derived Medications. Pediatr. Neurol. 2012; 47: 216–218 DOI: 10.1016/j.pediatrneurol.2012.05.013
    Back to article
  30. 30Morgan JC, Winter WC, Wooten GF. Amphetamine-induced chorea in attention deficit-hyperactivity disorder. Mov. Disord. 2004; 19: 840–842. DOI: 10.1002/mds.20081
    Back to article
  31. 31Downes, MA, Whyte IM. Amphetamine-induced movement disorder. Emerg. Med. Australas. 2005; 17: 277–280. DOI: 10.1111/j.1742-6723.2005.00735.x
    Back to article
  32. 32Rhee KJ, Albertson TE. Choreoathetoid Disorder Associated with Amphetamine-like Drugs. Am. J. Emerg. Med. 1988; 6: 131–133. DOI: 10.1016/0735-6757(88)90050-2
    Back to article
  33. 33Sperling LS, Horowitz JL. Methamphetamine-induced choreoathetosis and rhabdomyolysis. Ann. Intern. Med. 1994; 121: 986. DOI: 10.7326/0003-4819-121-12-199412150-00019
    Back to article
  34. 34Sutamtewagul G, Sood V, Nugent K. Sympathomimetic syndrome, choreoathetosis, and acute kidney injury following “bath salts” injection. Clin. Nephrol. 2014; 81: 63–6. DOI: 10.5414/CN107559
    Back to article
  35. 35Guay, DRP. Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders. Am. J. Geriatr. Pharmacother. 2010; 8: 331–373. DOI: 10.1016/j.amjopharm.2010.08.006
    Back to article
  36. 36Fernandez HH, et al. Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study. Neurology. 2017; 88: 2003–2010. DOI: 10.1212/WNL.0000000000003960
    Back to article
  37. 37Anderson KE, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. The lancet. Psychiatry. 2017; 4: 595–604. DOI: 10.1016/S2215-0366(17)30236-5
    Back to article
  38. 38Hauser RA, et al. KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia. Am. J. Psychiatry. 2017; 174: 476–484. DOI: 10.1176/appi.ajp.2017.16091037
    Back to article
  39. 39Woods SW, Saksa JR, Baker CB, Cohen SJ, Tek C. Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry. 2008; 69: 546–54. DOI: 10.4088/JCP.v69n0405
    Back to article
  40. 40Verhagen Metman L, et al. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson’s disease. Neurology. 1998; 50: 1323–1326. DOI: 10.1212/WNL.50.5.1323
    Back to article
  41. 41da Silva-Júnior FP, Braga-Neto P, Sueli Monte F, de Bruin VMS. Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study. Parkinsonism Relat. Disord. 2005; 11: 449–52. DOI: 10.1016/j.parkreldis.2005.05.008
    Back to article
  42. 42Del Dotto P, et al. Intravenous amantadine improves levadopa-induced dyskinesias: An acute double-blind placebo-controlled study. Mov. Disord. 2001; 16: 515–520. DOI: 10.1002/mds.1112
    Back to article
  43. 43Wolf E, et al. Long-term antidyskinetic efficacy of amantadine in Parkinson’s disease. Mov. Disord. 2010; 25: 1357–1363. DOI: 10.1002/mds.23034
    Back to article
  44. 44Ory-Magne F, et al. Withdrawing amantadine in dyskinetic patients with Parkinson disease: The AMANDYSK trial. Neurology. 2014; 82: 300–307. DOI: 10.1212/WNL.0000000000000050
    Back to article
  45. 45Deuschl G, et al. A Randomized Trial of Deep-Brain Stimulation for Parkinson’s Disease. N. Engl. J. Med. 2006; 355: 896–908.
    Back to article
  46. 46Follett KA. Comparison of pallidal and subthalamic deep brain stimulation for the treatment of levodopa-induced dyskinesias. Neurosurgical focus. 2004; 17: E3. DOI: 10.3171/foc.2004.17.1.3
    Back to article
  47. 47Wu YR, Levy R, Ashby P, Tasker RR, Dostrovsky JO. Does stimulation of the GPi control dyskinesia by activating inhibitory axons? Mov. Disord. 2001; 16: 208–16. DOI: 10.1002/mds.1046
    Back to article
  48. 48Weaver FM. et al. Parkinson’s disease medication use and costs following deep brain stimulation. Mov. Disord. 2012; 27: 1398–1403. DOI: 10.1002/mds.25164
    Back to article
  49. 49Mestre TA, Ferreira JJ, Pimentel J. Putaminal petechial haemorrhage as the cause of non-ketotic hyperglycaemic chorea: A neuropathological case correlated with MRI findings 7. Journal of Neurology, Neurosurgery and Psychiatry. 2007; 78: 549–550. DOI: 10.1136/jnnp.2006.105387
    Back to article
  50. 50Cardoso S, et al. Impact of STZ-induced hyperglycemia and insulin-induced hypoglycemia in plasma amino acids and cortical synaptosomal neurotransmitters. Synapse. 2011; 65: 457–466. DOI: 10.1002/syn.20863
    Back to article
  51. 51Shan DE, Ho DMT, Chang C, Pan HC, Teng, MMH. Hemichorea-hemiballism: An explanation for MR signal changes. Am. J. Neuroradiol. 1998; 19: 863–870.
    Back to article
  52. 52Arifi B, Gupta S, Sharma S, Daraboina A, Ahuja SA. Case Report of Chorea Associated with Hyperthyroidism. J. Clin. DIAGNOSTIC Res. 2016; 10: PL01. DOI: 10.7860/JCDR/2016/17299.7277
    Back to article
  53. 53Baba M, et al. Persistent hemichorea associated with thyrotoxicosis. Intern. Med. 1992; 31: 1144–6. DOI: 10.2169/internalmedicine.31.1144
    Back to article
  54. 54Isaacs JD, Rakshi J, Baker R, Brooks DJ, Warrens AN. Chorea associated with thyroxine replacement therapy. Mov. Disord. 2005; 20: 1656–1657. DOI: 10.1002/mds.20603
    Back to article
  55. 55Hayashi R, Hashimoto T, Tako K. Efficacy of propranolol in hyperthyroid-induced chorea: A case report. Mov. Disord. 2003; 18: 1073–1076. DOI: 10.1002/mds.10477
    Back to article
  56. 56Pathania M, Upadhyaya S, Lali BS, Sharma A. Chorea gravidarum: a rarity in West still haunts pregnant women in the East. BMJ Case Rep. 2013; 2012–2014. DOI: 10.1136/bcr-2012-008096
    Back to article
  57. 57Maia D, et al. Pregnancy in patients with Sydenham’s chorea. Park. Relat. Disord. 2012; 18: 458–461. DOI: 10.1016/j.parkreldis.2011.12.013
    Back to article
  58. 58Sosa, BO, Toral, JAB. Identifying the aetiology of sudden acute abnormal involuntary movements in a primigravid. BMJ Case Rep. 2018; 11: e227112. DOI: 10.1136/bcr-2018-227112
    Back to article
  59. 59Nausieda PA, et al. Chronic dopaminergic sensitivity after Sydenham’s chorea. Neurology. 1983; 33: 750–4. DOI: 10.1212/WNL.33.6.750
    Back to article
  60. 60Sharmila V, Babu TA. Oral contraceptive pills induced hemichorea in an adolescent female with polycystic ovarian disease. Indian J. Pharmacol. 2015; 47: 232–3. DOI: 10.4103/0253-7613.153440
    Back to article
  61. 61Natera-Villalba E, et al. Simultaneous acute presentation of generalized chorea and subacute combined degeneration secondary to vitamin B12 deficiency. Parkinsonism Relat. Disord. 2018; 55: 2–4. DOI: 10.1016/j.parkreldis.2018.09.006
    Back to article
  62. 62Battista J, Walker R. Chorea: Classification, Differential, Diagnosis, and Treatment. Scientific American Neurology; 2015. Available at: https://www.deckerip.com/products/scientific-american-neurology/.
    Back to article
  63. 63Espinosa G, Cervera R. Current treatment of antiphospholipid syndrome: lights and shadows. Nat. Rev. Rheumatol. 2015; 11: 1–11. DOI: 10.1038/nrrheum.2015.88
    Back to article
  64. 64Peluso S, et al. Antiphospholipid-related chorea. Front. Neurolgoy. 2012; 3: 1–7. DOI: 10.3389/fneur.2012.00150
    Back to article
  65. 65O’Toole O, et al. Autoimmune chorea in adults. Neurology. 2013; 80: 1133–44. DOI: 10.1212/WNL.0b013e3182886991
    Back to article
  66. 66Paus S, Pötzsch B, Risse JH. Chorea and antiphospholipid antibodies: Treatment with methotrexate. Neurology. 2011; 23–26.
    Back to article
  67. 67Yokoyama K, Mori M, Yoshida A. Mycophenolate mofetil therapy for two cases of antiphospholipid antibody-associated chorea. Mod. Rheumatol. 2018; 28: 709–711. DOI: 10.3109/14397595.2015.1134035
    Back to article
  68. 68Lazurova I, et al. Efficacy of intravenous immunoglobulin treatment in lupus erythematosus chorea. Clin. Rheumatol. 2007; 26: 2145–2147. DOI: 10.1007/s10067-007-0627-9
    Back to article
  69. 69Ramdhani RA, Frucht SJ. Isolated Chorea Associated with LGI1 Antibody. Tremor Other Hyperkinet. Mov. (N. Y). 2014; Jan 8. DOI: 10.5334/tohm.214
    Back to article
  70. 70Hadjivassiliou M, Davies-Jones, GaB, Sanders DS, Grünewald, RA. Dietary treatment of gluten ataxia. J. Neurol. Neurosurg. Psychiatry. 2003; 74: 1221–4. DOI: 10.1136/jnnp.74.9.1221
    Back to article
  71. 71Walker RH. Further Evidence for Celiac Disease-associated Chorea? Tremor and Other Hyperkinetic Movements; 2011. DOI: 10.5334/tohm.80
    Back to article
  72. 72Pereira AC, et al. Choreic syndrome and coeliac disease: a hitherto unrecognised association. Mov. Disord. 2004; 19: 478–82. DOI: 10.1002/mds.10691
    Back to article
  73. 73Miranda M, et al. Movement disorders in non-encephalopathic Hashimoto’s thyroiditis. Parkinsonism and Related Disorders. 2018; 55: 141–142. DOI: 10.1016/j.parkreldis.2018.06.008
    Back to article
  74. 74Taurin G, et al. Choreic syndrome due to Hashimoto’s encephalopathy. Mov. Disord. 2002; 17: 1091–1092. DOI: 10.1002/mds.10230
    Back to article
  75. 75Feinstein E, Walker R. An Update on the Treatment of Chorea. Curr. Treat. Options Neurol. 2018; 20: 44. DOI: 10.1007/s11940-018-0529-y
    Back to article
  76. 76Abbruzzese G, et al. A pilot trial of deferiprone for neurodegeneration with brain iron accumulation. Haematologica. 2011; 96: 1708–1711. DOI: 10.3324/haematol.2011.043018
    Back to article
  77. 77Levi S, Finazzi D. Neurodegeneration with brain iron accumulation: Update on pathogenic mechanisms. Frontiers in Pharmacology. 2014; 5 MAY: 99. DOI: 10.3389/fphar.2014.00099
    Back to article
  78. 78Forni GL, et al. Regression of symptoms after selective iron chelation therapy in a case of neurodegeneration with brain iron accumulation. Mov. Disord. 2008; 23: 905–908. DOI: 10.1002/mds.22002
    Back to article
  79. 79Miyajima H. Aceruloplasminemia. GeneReviews(®); 1993.
    Back to article
  80. 80Miyajima H, et al. Use of desferrioxamine in the treatment of aceruloplasminemia. Ann. Neurol. 1997; 41: 404–407. DOI: 10.1002/ana.410410318
    Back to article
  81. 81Suzuki Y, et al. Effectiveness of oral iron chelator treatment with deferasirox in an aceruloplasminemia patient with a novel ceruloplasmin gene mutation. Intern. Med. 2013; 52: 1527–30. DOI: 10.2169/internalmedicine.52.0102
    Back to article
  82. 82Kono S. Aceruloplasminemia. In: International review of neurobiology. 2013; 110: 125–151. DOI: 10.1016/B978-0-12-410502-7.00007-7
    Back to article
  83. 83Kumar N, Rizek P, Jog M. Neuroferritinopathy: Pathophysiology, Presentation, Differential Diagnoses and Management. Tremor Other Hyperkinet. Mov. (N. Y). 2016; 6: 355. DOI: 10.5334/tohm.317
    Back to article
  84. 84Mancuso M, et al. Hereditary ferritinopathy: a novel mutation, its cellular pathology, and pathogenetic insights. J. Neuropathol. Exp. Neurol. 2005; 64: 280–94. DOI: 10.1093/jnen/64.4.280
    Back to article
  85. 85Zhou B, et al. A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. Nat. Genet. 2001; 28: 345–349. DOI: 10.1038/ng572
    Back to article
  86. 86Poli L, et al. Is aceruloplasminemia treatable? Combining iron chelation and fresh-frozen plasma treatment. Neurol. Sci. 2017; 38: 357–360. DOI: 10.1007/s10072-016-2756-x
    Back to article
  87. 87Skidmore FM, et al. Aceruloplasminaemia with progressive atrophy without brain iron overload: treatment with oral chelation. J. Neurol. Neurosurg. Psychiatry. 2008; 79: 467–470. DOI: 10.1136/jnnp.2007.120568
    Back to article
  88. 88Chinnery PF, et al. Clinical features and natural history of neuroferritinopathy caused by the FTL1 460InsA mutation. Brain. 2007; 130: 110–9. DOI: 10.1093/brain/awl319
    Back to article
  89. 89Lehn A, Boyle R, Brown H, Airey C, Mellick G. Neuroferritinopathy. Parkinsonism Relat. Disord. 2012; 18: 909–915. DOI: 10.1016/j.parkreldis.2012.06.021
    Back to article
  90. 90Ondo WG, Adam OR, Jankovic J, Chinnery, PF. Dramatic response of facial stereotype/tic to tetrabenazine in the first reported cases of neuroferritinopathy in the United States. Mov. Disord. 2010; 25: 2470–2472. DOI: 10.1002/mds.23299
    Back to article
  91. 91Leen WG, et al. GLUT1 deficiency syndrome into adulthood: A follow-up study. J. Neurol. 2014; 261: 589–599. DOI: 10.1007/s00415-014-7240-z
    Back to article
  92. 92Chen WJ, et al. Exome sequencing identifies truncating mutations in PRRT2 that cause paroxysmal kinesigenic dyskinesia. Nat. Genet. 2011; 43: 1252–1255. DOI: 10.1038/ng.1008
    Back to article
  93. 93Jankovic J, Demirkiran M. Classification of paroxysmal dyskinesias and ataxias. Adv. Neurol. 2002; 89: 387–400.
    Back to article
  94. 94Bruno MK, et al. Clinical evaluation of idiopathic paroxysmal kinesigenic dyskinesia: New diagnostic criteria. Neurology. 2004; 63: 2280–2287. DOI: 10.1212/01.WNL.0000147298.05983.50
    Back to article
  95. 95Pan G, Zhang L, Zhou, S. Clinical features of patients with paroxysmal kinesigenic dyskinesia, mutation screening of PRRT2 and the effects of morning draughts of oxcarbazepine. BMC Pediatr. 2019; 19. DOI: 10.1186/s12887-019-1798-7
    Back to article
  96. 96Waln O, Jankovic J. Paroxysmal movement disorders. Neurol. Clin. 2015; 33: 137–152. DOI: 10.1016/j.ncl.2014.09.014
    Back to article
  97. 97Bandmann O, Weiss KH, Kaler SG. Wilson’s disease and other neurological copper disorders. Lancet. 2015; 14: 103–113. DOI: 10.1016/S1474-4422(14)70190-5
    Back to article
DOI: https://doi.org/10.5334/tohm.351 | Journal eISSN: 2160-8288
Journal RSS Feed
Language: English
Submitted on: May 14, 2020
Accepted on: May 20, 2020
Published on: Jul 16, 2020
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
chorea,
VMAT2 inhibitor,
tardive dyskinesia,
levodopa-induced dyskinesia,
amphetamine,
chorea gravidarum,
autoimmune,
brain iron accumulation disorders

© 2020 Erin Feinstein, Ruth Walker, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.

Previous articleVolume 10 (2020): Issue 0Next article